Halozyme Therapeutics (HALO) Posts Q4 EPS of $0.50
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $115.13 --0%
EPS Growth %: +30.8%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: +30.8%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.50, which may not compare to the analyst estimate of $0.53. Revenue for the quarter came in at $121.7 million versus the consensus estimate of $120.16 million.
GUIDANCE:
Halozyme Therapeutics sees FY2021 EPS of $1.40-$1.55, which may not compare to the consensus of $1.70. Halozyme Therapeutics sees FY2021 revenue of $375-395 million, versus the consensus of $400.15 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- General Mills (GIS) Tops Q1 EPS by 3c
- Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
- Oppenheimer Starts Viatris (VTRS) at Outperform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
